CD19 and neoplasm: This indicates that the dual-targeting CAR domain can recognize and bind tumor cells with just one homologous antigen, enabling CD19/CD20 CAR-NK cells to lyse CD19+CD20− or CD19−CD20+ tumor cells in case of CD19 or CD20 tumor escape.